Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by g-Che Chen.
International Journal of Urology | 2012
Cheng-Che Chen; Yen-Chuan Ou; Cheng-Kuang Yang; Kun-Yuan Chiu; Shian-Shiang Wang; Chung-Kuang Su; Hao-Chung Ho; Chen-Li Cheng; Chuan-Shu Chen; Jian-Ri Lee; Wen-min Chen
Objectives: To analyze the incidence of malfunction of the da Vinci robotic system in a single center and to provide potential solutions.
Frontiers in Pharmacology | 2017
Jian-Ri Li; Shian-Shiang Wang; Cheng-Kuang Yang; Chuan-Su Chen; Hao-Chung Ho; Kun-Yuan Chiu; Chi-Feng Hung; Chen-Li Cheng; Chi-Rei Yang; Cheng-Che Chen; Shu-Chi Wang; Chia-Yen Lin; Yen-Chuan Ou
Introduction: We performed a chart review study in our castration-resistant prostate cancer (CRPC) patients who received Abiraterone acetate (AA) treatment after docetaxel and identified clinical markers which can predict treatment outcome. Materials and Methods: From 2012 to 2016, 64 patients who received docetaxel after CRPC followed by AA treatment were included. Clinical parameters were recorded and analysis was performed to identify associations between pre-treatment variables and treatment outcome. Results: Thirty three patients (51.6%) achieved a decrease in PSA of 50%. The median PSA progression-free survival and overall survival in the total cohort of 64 patients were 6.6 and 24 months, respectively. Adverse events (AEs) in all grades developed in 35.9% (23/64) patients and mostly were grade 1 or 2. The most common AEs were gastric upset, hypokalemia and elevated liver function tests. Of the eight variables analyzed, first line androgen deprivation therapy (ADT) duration showed positive association to progression free survival (HR 0.98, 95% CI [0.96–0.99], p = 0.012) and overall survival (HR 0.97, 95% CI [0.94–0.99], p = 0.019). Pre-AA PSA and PSA progression ratio showed negative association only to progression free survival (HR 1.0, 95% CI [1.000–1.002], p = 0.025, HR 1.01, 95% CI [1.00–1.01], p < 0.001, respectively). Conclusion: First line ADT duration was positively associated with AA treatment efficacy in progression free survival and overall survival. It can be used as a pre-treatment predictor.
Biofactors | 2018
Jian-Ri Li; Kun-Yuan Chiu; Yen-Chuan Ou; Shian-Shiang Wang; Chuan-Su Chen; Cheng-Kuang Yang; Hao-Chung Ho; Chen-Li Cheng; Chi-Rei Yang; Cheng-Che Chen; Shu-Chi Wang; Chia-Yen Lin; Sheng-Chun Hung; Chiann-Yi Hsu; Chun-Jung Chen
Fibroblast growth factors (FGF) 19, 21, and 23 have been reported as functional factors in human metabolic diseases and malignancies. We performed a prospective survey to compare circulating FGF levels in urothelial carcinoma (UC) patients and normal controls. Between 2016 and 2017, 39 patients with UC of the urinary bladder or upper urinary tract who received surgical intervention were included. All the serum samples were obtained before surgeries. The control group included 28 healthy volunteers. Analysis of the circulating FGF19, 21, and 23 levels among all 67 subjects, as well as a subgroup analysis of the 39 UC patients were performed. The median levels of serum FGF19, 21, and 23 in the UC patients were 84.2, 505.3, and 117.6 pg/mL, respectively, which were statistically different from levels found in the healthy controls (P = 0.015, <0.001 and < 0.001, respectively). In the subgroup analysis, the FGF19 and FGF21 levels were significantly higher in end-stage renal disease UC patients, while FGF21 was also higher in the UC patients with cardiovascular diseases and history of recurrent UC. In the receiver operating characteristic (ROC) curve analysis, FGF19, 21, and 23 were all significant predictors of UC [area under the curve (AUC)] 0.674, P = 0.015; AUC 0.918, P < 0.001; AUC 0.897, P < 0.001, respectively). In UC patients, serum FGF19 level was significantly lower, while FGF21 and 23 were significantly higher, than respective levels in healthy controls. All three markers may serve as good predictors of UC occurrence, and FGF21 level was associated with disease recurrence.
Anticancer Research | 2018
Jian-Ri Li; Yen-Chuan Ou; Cheng-Kuang Yang; Shian-Shiang Wang; Chuan-Su Chen; Hao-Chung Ho; Chen-Li Cheng; Chi-Rei Yang; Cheng-Che Chen; Shu-Chi Wang; Chia-Yen Lin; Sheng-Chun Hung; Chiann-Yi Hsu; Kun-Yuan Chiu
Background/Aim: We performed a retrospective survey on our metastatic renal cell carcinoma (MRCC) patients who had received targeted therapies, and afterwards evaluated the clinical impacts of local interventions on the patient outcomes. Materials and Methods: Between 2006 and 2016, 124 patients with MRCC who had received at least one line of tyrosine kinase inhibitors or mammalian target of rapamycin were included in the study. Seventy-five patients (60.5%) received targeted therapies only, twenty-six patients received complete resection and the remaining 23 received incomplete local interventions for their metastatic lesions. Analysis of the basic characteristics, overall survival and multi-variant regression amongst the three groups was performed. Results: The age, gender distribution, tumor cell type, targeted therapy selection, line of therapies and sites of metastases were not different amongst the three groups. The targeted therapy-only group had a significantly higher percentage of Memorial Sloan Kettering Cancer Center (MSKCC) poor-risk patients compared with the other two groups (22.7% vs. 3.8% and 0%, p=0.006 respectively). The targeted treatment duration and follow-up duration was significantly shorted in the targeted therapy-only group. Of the twelve variables analyzed, complete resection and MSKCC poor-risk group showed a significant impact on the overall survival rate (HR=0.5, 95%CI=0.25-0.98, p=0.045; HR=2.97, 95%CI=1.05-8.4, p=0.04 respectively). Conclusion: Complete resection of metastatic sites for MRCC patients, combined with targeted therapy, could provide better overall survival rates than targeted therapy alone. Poor MSKCC risk is still correlated to a poor outcome in the current targeted therapy era.
Journal of The Chinese Medical Association | 2017
Shu-Chi Wang; Cheng-Che Chen; Cheng-Kuang Yang; Siu-Wan Hung; Yee-Jee Jan; Yen-Chuan Ou
Background: In order to prevent over treatment of prostate cancer and significant adverse effects after surgical intervention, active surveillance was suggested in low risk or very low risk patients. This study aimed to retrospectively analyze the adverse pathological results of candidates eligible for active surveillance. Methods: A total of 904 patients underwent robot‐assisted laparoscopic radical prostatectomy in this single institute, from 2005 to April 2014. One hundred and thirty‐two patients were eligible for active surveillance (AS). Candidates for active surveillance were defined as low risk (T1/T2a, prostate specific antigen 10 ng/ml or less, and Gleason score 6 or less) and very low risk (T1c, prostate specific antigen density 0.15 or less, Gleason score 6 or less, 2 or fewer positive biopsy cores, 50% or less cancer involvement per core) patients. Adverse pathological results were defined as Gleason sum more than 6, and non‐organ‐confined disease. Results: There were 132 patients eligible for active surveillance. One hundred and thirteen (85.6%, 113/132) patients had low risk disease and nineteen (14.4%, 19/132) patients had very low risk disease. The adverse pathological results of low risk disease were upgrading Gleason sum and non‐organ‐confined disease, 41.6% (47/113) and 28.3% (32/113), respectively. The adverse pathological results of very low risk disease were upgrading Gleason sum and non‐organ‐confined disease, 15.8% (3/19) and 15.8% (3/19), respectively. Conclusion: We conclude that although AS may prevent over treatment and significant adverse effects after surgical intervention, stratification of patients with low risk prostate cancer is of paramount importance when choosing appropriate candidate for AS. The risk of adverse pathological results should be well informed in the pretreatment counseling.
Frontiers in Pharmacology | 2017
Jian-Ri Li; Kun-Yuan Chiu; Shian-Shiang Wang; Cheng-Kuang Yang; Chuan-Shu Chen; Hao-Chung Ho; Chi-Feng Hung; Chen-Li Cheng; Chi-Rei Yang; Cheng-Che Chen; Shu-Chi Wang; Chia-Yen Lin; Chao-Hsiang Chang; Chiann-Yi Hsu; Yen-Chuan Ou
Introduction: Conventional anti-androgen regimens were widely used as an initiation or combined androgen blockade (CAB) therapy in advanced prostate cancer patients. Currently, new androgen pathway inhibitors such as abiraterone acetate (AA) and enzalutamide had been proven effective in metastatic castration resistant prostate cancer. In this study, we attempt to analyze the role of conventional anti-androgen drugs as deferred CAB therapy in castration-resistant prostate cancer patients. Materials and Methods: From 2012 to 2017, 48 metastatic castration-resistant prostate cancer (CRPC) patients who received sequential treatments with primary androgen blockade, oral anti-androgen regimens, and docetaxel followed by AA treatment were included. We defined effective deferred CAB as any decline of PSA after add-on antiandrogen after CRPC. Patients were separated into effective and ineffective deferred CAB. Comparison between two groups in the first line androgen deprivation therapy duration, CRPC PSA level, pre-AA PSA level, chemotherapy dosages, duration, and patients progression free survival and overall survival after AA treatment were analyzed. Results: Twenty-three patients (47.9%) achieved PSA decline after deferred CAB. Among total 48 patients, 24 patients experienced PSA decline more than 50% after AA treatment. The median PSA progression-free survival and overall survival after AA treatment in the total cohort of 48 patients were 4.4 and 24.3 months, respectively. The effective deferred CAB group showed significantly lower PSA level, lower percentage of PSA progression, higher total follow-up duration, higher percentage of surviving patients, better progression free survival, and overall survival estimate after AA treatment. Of the eight variables analyzed, effectiveness in deferred CAB showed positive association to progression free survival (HR 0.29, 95% CI 0.12–0.67, p = 0.004) and overall survival (HR 0.24, 95% CI 0.07–0.81, p = 0.022). First line androgen deprivation therapy (ADT) duration also showed positive association to overall survival (HR 0.95, 95% CI 0.91–0.99, p = 0.023). Conclusions: Effectiveness of deferred CAB therapy was positively associated with progression free survival and overall survival of AA treatment after docetaxel. It can be used as a pre-treatment predictor.
Oncology Reports | 2017
Sheau-Yun Yuan; Chen-Li Cheng; Shian-Shiang Wang; Hao-Chung Ho; Kun-Yuan Chiu; Chuan-Shu Chen; Cheng-Che Chen; Ming-Yuh Shiau; Yen-Chuan Ou
Journal of The Formosan Medical Association | 2015
Cheng-Che Chen; Cheng-Kuang Yang; Siu-Wan Hung; John Wang; Yen-Chuan Ou
Oncology Reports | 2017
Sheau-Yun Yuan; Ming-Yuh Shiau; Yen-Chuan Ou; Yu-Chia Huang; Cheng-Che Chen; Chen-Li Cheng; Kun-Yuan Chiu; Shian-Shiang Wang; Kan-Jen Tsai
Urological Science | 2016
Po-Chi Liao; Hao-Chung Ho; Kun-Yuan Chiu; Chuan-Shu Chen; Chi-Feng Hung; Chen-Li Cheng; Jian-Ri Li; Shian-Shiang Wang; Cheng-Kuang Yang; Cheng-Che Chen; Yen-Chuan Ou